All In Biotech

Drug Trial Radar · NCT00036166

Study of FK463 for the Treatment of Invasive Aspergillosis

An Open-Label, Non-Comparative Study of FK463 for the Treatment of Invasive Aspergillosis

Last checked: Nov 19, 2026Latest source record: Jan 10, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

326

Actual

Start

Jan 29, 1999

Primary completion

Jan 31, 2002

Study completion Jan 31, 2002

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
May 9, 2002

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the safety and efficacy of FK463 in patients with proven or probable invasive infections due to Aspergillus species.

Conditions

  • Aspergillosis

Interventions

  • FK463Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

23 sites in 8 countries. Site status is shown where the registry gives one.

  • Medizinische Univ.-Klinik

    Graz, Austria

  • Krankenhaus Elisabethinen Linz

    Linz, Austria

  • Hopital Henri Mondor, Service d'Hematologie Clinique

    Créteil, France

  • Hotel Dieu, Service d'Hematologie

    Nantes, France

  • Hopital Saint Louis, Service D'Hematologie/Greffe de Moelle

    Paris, France

  • Hopital Necker Enfants Malades, Service d'Hematologie

    Paris, France

  • Johann Wolfgang Goethe Universitat, Medizinische Klinik III

    Frankfurt, Germany

  • Westpfalz Krankehaus

    Kaiserslautern, Germany

  • Medizinische Klinik und Poliklinik II, Abt. Hamatologie und Onkologie

    Leipzig, Germany

  • Klinikum der Stadt, Medizinische Klinik A

    Ludwigshafen, Germany

  • Uniklinik Mainz

    Mainz, Germany

  • LMU Munchen, Hamatopoetische Zell - Transplantation

    München, Germany

  • Universitat Wurzburg, Institut fur Molekulare und Infectionsbiologie

    Würzburg, Germany

  • Nationale Institute for Cancer Research

    Genova, Italy

  • Ospedale Niguarda-Ca Granda, Dept. of Internal Medicine Padiglione Brera

    Milan, Italy

  • Institute of Haematology and Blood Transfusion

    Warsaw, Poland

  • Hospital Clinic I provencial, Servicio Enfermadades Infecciosas

    Barcelona, Spain

  • Hospital Gregorio Maranon, Servicio de Enfermadades Infecciosas

    Madrid, Spain

  • Hospital Doce de Octubre, Servicio de Microbiologia y Enfermadades Infecciosas

    Madrid, Spain

  • Huddinge University Hospital, Dept. of Transplantation Surgery/Immunology

    Huddinge, Sweden

  • Royal Free Hospital, Dept. of Haematological Oncology

    London, United Kingdom

  • Christie Hospital NHS Trust

    Manchester, United Kingdom

  • Royal Marsden Hospital

    Sutton Surrey, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.